Ranjan Pai is among India’s most influential investors. So, when he makes a move into senior care, it is time to sit up and take notice of the sector, not to mention the broader grey economy.
Related Posts
Ozempic, Wegovy, Mounjaro: Are GLP-1 drugs weight loss wonders or health gamble?
India, home to the world’s largest low- and middle-income (LMIC) population, is now facing a weighty challenge — literally. It accounts for a staggering 15% of the global obesity burden, and by 2040, almost half of the Indian population is projected to be overweight or obese. The latest National Family Health Survey (NFHS-5) reveals a […]
Can Cipla make inhaled insulin a successful option for diabetes patients?
Umang Vohra, Global CEO, Cipla. Will Cipla’s big bet work?; image credit: Company. Synopsis Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing Afrezza, an inhaled insulin, in India. Will doctors and patients buy this option? A blue travel case of insulin injections is […]
Indian doctors: From Kanjivarams to Thai trips: inside the toxic give-and-take between pharma companies and doctors
Doctors have earned a place of reverence and high esteem in Indian society. They have been known to selflessly care for patients, a trait that was in ample display during the pandemic. Some of them even sacrificed their lives in the call of duty. But as happens in every profession, medical practice has its share […]
